English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Growth Factor Cocktail (GFC), which contains growth factors and cytokine, has been gradually gaining attention as a new treatment for hair loss. Several studies reported the effectiveness of GFC on hair regrowth via microneedles; however, studies regarding formulations with fibroblast growth factor 5 short (FGF5s) and nicotinamide mononucleotide (NMN) have not been conducted. Objective: This study aimed to investigate the effect of treatment with microneedle technology by adding FGF5s and NMN to GFC in patients with androgenetic alopecia (AGA). Methods: In this study, AGA patients were treated six times for a total of 3 months at 2-week intervals from the first visit. The scalp was divided into two sections at the time of treatment; the right side was treated with GFC with FGF5s and NMN, and the left were treated with normal saline, with microneedles to a depth of 0.8 mm. A total of 20 patients (11 males and 9 females) were included in the study. Clinical photographs and phototrichogram were performed before and 2 weeks after treatment to determine the final treatment effect. Results: The phototrichogram images of the scalp treated with GFC for 3 months showed increased hair density and diameter. In contrast, there was no change in hair density and diameter in the scalp treated with normal saline. Conclusion: GFC with FGF5s and NMN with microneedling is an effective and safe treatment of androgenetic alopecia. Future studies with more thorough investigations in controlled clinical settings are warranted. *Correspondence to: Byung In Ro, M.D., Ph.D., Invited Professor, Department of Dermatology, Myongji Hospital, Hanyang University College of Medicine, Goyang 10475, Korea, Tel: +82-31-810-7050; Fax: +82-31-810-7057; E-mail: drro@mjh.or.kr

global dermatology

Therapeutic effects of growth factor cocktail (CellcurinTM) containing FGF5s (fibroblast growth factor 5 short) and NMN (nicotinamide mononucleotide) in patients with androgenetic alopecia: A split study